Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (648 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Nippon India Index Fund - Nifty 50 |
|---|---|
| 03 Jan 2013 | ₹100.00 |
| 22 Feb 2014 | ₹103.06 |
| 13 Apr 2015 | ₹149.26 |
| 31 May 2016 | ₹138.82 |
| 20 Jul 2017 | ₹169.08 |
| 08 Sep 2018 | ₹200.44 |
| 28 Oct 2019 | ₹202.65 |
| 15 Dec 2020 | ₹238.45 |
| 03 Feb 2022 | ₹311.39 |
| 25 Mar 2023 | ₹303.64 |
| 13 May 2024 | ₹400.10 |
| 01 Jul 2025 | ₹468.38 |
| 20 Aug 2026 | ₹450.20 |
| Metric | Nippon India · Direct · Bonus NAV ₹44.76 Very High risk ★★★★☆ | Category median Index Funds · 648 funds |
|---|---|---|
| -2.31% | +5.58% | |
| +8.91% | +8.01% | |
| +9.11% | +9.10% | |
| +11.76% | +11.55% | |
| +11.67% | +7.61% | |
| +7.49% | — | |
| +12.84% | +11.67% | |
| +13.14% | +13.31% | |
| +12.86% | +12.77% | |
| Risk | ||
| 13.20% | 13.65% | |
| 0.18 | 0.18 | |
| 0.26 | 0.26 | |
| -38.17% | -16.10% | |
| Nifty 50 | — | |
| +0.98% | +0.65% | |
| 1.00 | 1.00 | |
| 102.2% | 102.2% | |
| 96.4% | 97.7% | |
| 0.14% | 0.35% | |
| ₹3,656Cr | ₹182.17Cr | |
| None | — | |
| None | — | |
| — | — | |
| ₹100 | — | |
| — | 36% | |
| Himanshu Mange | — | |
| 03 Jan 2013 | — | |
| — | — | |
| — | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.